Where there’s a gap, there’s an opportunity. GEN spoke with Parviz Shamlou, PhD, from Jefferson Institute for Bioprocessing, about its 25,000 sq. ft. fully flexible state-of-the-art facility that will significantly advance the bioprocessing world.
Regenerative medicine looks forward to the industrial-scale production of diverse tissues. Eventually, treatments may grant patients something like the powers of a superhero—a Salamander Man—when needed.
High seeding efficiencies and improved outgrowth of clones can be achieved, says Solentim, by combining a CHO knockout cell line, the right media, and the VIPS platform.
The deal is designed to accelerate Avalon’s standardization, automation, and bioproduction for clinical-grade Chimeric Antigen Receptor (CAR)-T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV) based regenerative therapeutics.
EQT will focus on helping to advance Aldevron’s R&D and innovation efforts in genetic medicine and will also support Aldevron with investments in additional production capacity at the Fargo campus.
Synthetic biologists have built a modular, tunable protein switch that can sense environmental stimuli and respond by modifying cell functions such as the control of gene expression, the management of cellular traffic, the degradation of specific proteins, and the orchestration of protein-binding interactions.
New bacterial pathway harnesses ribosomal peptide synthesis to produce a scaffold, likened to a baker's sourdough starter, and enzyme-mediated addition of amino acid and modification.
Please wait while you are redirected to the right page...